Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4 USD | +0.50% |
|
-3.85% | -14.89% |
06-11 | MaxCyte CEO Maher Masoud buys 100,000 shares | AN |
06-11 | Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing | MT |
Business Summary
Number of employees: 143
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell Therapy
55.3
%
| 31 | 69.0 % | 23 | 55.3 % | -25.26% |
Program-related
27.8
%
| 5 | 10.4 % | 11 | 27.8 % | +148.38% |
Drug Discovery
16.9
%
| 9 | 20.6 % | 7 | 16.9 % | -23.14% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 44 | 100.0 % | 41 | 100.0 % | -6.72% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 26/03/23 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ron Holtz
ADM | Chief Administrative Officer | 66 | 31/12/04 |
Corporate Officer/Principal | - | 20/08/23 | |
Gene Zhu
LAW | General Counsel | - | - |
Jill Mayer
HRO | Human Resources Officer | - | 31/12/17 |
Thomas Ross
SAM | Sales & Marketing | 63 | 14/10/14 |
Steven Nardi
PRN | Corporate Officer/Principal | - | 12/10/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 30/11/22 |
Art Mandell
BRD | Director/Board Member | 71 | 30/04/06 |
Will Brooke
BRD | Director/Board Member | 68 | 29/02/04 |
Stanley Erck
BRD | Director/Board Member | 76 | 31/12/04 |
Ron Holtz
ADM | Chief Administrative Officer | 66 | 31/12/04 |
John Johnston
BRD | Director/Board Member | 65 | 31/12/15 |
Richard Douglas
CHM | Chairman | 71 | 11/02/18 |
Yasir Al-Wakeel
BRD | Director/Board Member | 42 | 14/06/21 |
Rekha Hemrajani
BRD | Director/Board Member | 54 | 14/06/21 |
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 104,544,289 | 97,857,767 ( 93.60 %) | 0 | 93.60 % |
Company contact information
![address MaxCyte, Inc.(MXCT)](https://cdn.zonebourse.com/static/address/120797722.png)
Sector
Sales per Business
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.77% | 210B | |
+8.83% | 186B | |
+31.94% | 158B | |
+33.19% | 113B | |
+5.25% | 66.13B | |
+22.41% | 56.25B | |
+1.34% | 49B | |
-5.92% | 38.16B | |
+1.94% | 35.98B |
- Stock Market
- Equities
- MXCT Stock
- MXCT Stock
- Company MaxCyte, Inc.